Jefferies maintains Accentia at hold

Accentia Biopharmaceuticals, Inc. was maintained by Jefferies & Co., Inc. analyst Adam A. Walsh at a hold rating and $7 price target as the company and investors await resolution of regulatory status on Accentia's SinuNase product for chronic rhinosinusitis. Recent phase 2 trial results for the company's BiovaxID product for non-Hodgkin's lymphoma were encouraging and Jefferies said it considers the product a free-call option. Shares of the Tampa, Fla., pharmaceutical company were unchanged at $6.30 on volume of 188,932 shares versus the three-month running average of 50,077 shares. (Nasdaq: ABPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.